• Something wrong with this record ?

Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR)

SF. Seys, S. Schneider, J. de Kinderen, S. Reitsma, C. Cavaliere, PV. Tomazic, C. Morgenstern, G. Mortuaire, M. Wagenmann, G. Bettio, A. Ciofalo, Z. Diamant, J. Eckl-Dorna, WJ. Fokkens, C. Holzmeister, G. Mariën, S. Masieri, J. Otten, K....

. 2025 ; 155 (2) : 451-460. [pub] 20241031

Language English Country United States

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc25010109

BACKGROUND: Pivotal studies with dupilumab demonstrated clinically relevant improvements in nasal polyp score, symptom score, and quality-of-life score in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: We evaluated the effectiveness of dupilumab in a large-scale CRSwNP cohort from 6 European tertiary-care centers. METHODOLOGY: Nasal polyp score, Sinonasal Outcome Test 22 score, visual analog scale for total sinus symptoms, loss of smell, and nasal blockage, and Asthma Control Test (ACT) score were collected from hospital records and assessed at baseline and again at 24 and 52 weeks' treatment with dupilumab in CRSwNP patients. Treatment effectiveness was evaluated in relation to demographic and lifestyle factors, sinus surgery history, presence of comorbidities, and blood eosinophil counts (BEC). Treatment response was evaluated according to European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) 2021 criteria. RESULTS: All patient outcomes improved at 24 and 52 weeks' treatment compared to baseline. Dupilumab showed effectiveness independent of age, sex, body mass index, smoking status, prior sinus surgery, presence of asthma, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease, allergy, or baseline BEC. A total of 92.5% and 94.4% showed an improvement in at least 1 EUFOREA criterion at 24 and 52 weeks, respectively; 54.4% and 68.2% met all 4 of the more stringent EUFOREA criteria at 24 and 52 weeks, respectively. CONCLUSIONS: Real-world evaluation of dupilumab effectiveness demonstrates a robust and sustained response in at least two thirds of patients at 52 weeks' treatment. Favorable treatment response was independent of the number of sinus surgery procedures, major comorbidities, or baseline systemic levels of type 2 inflammation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010109
003      
CZ-PrNML
005      
20250429134647.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jaci.2024.10.016 $2 doi
035    __
$a (PubMed)39486595
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Seys, Sven F $u Galenus Health, Hasselt, Belgium. Electronic address: sven.seys@galenus.health
245    10
$a Real-world effectiveness of dupilumab in a European cohort of chronic rhinosinusitis with nasal polyps (CHRINOSOR) / $c SF. Seys, S. Schneider, J. de Kinderen, S. Reitsma, C. Cavaliere, PV. Tomazic, C. Morgenstern, G. Mortuaire, M. Wagenmann, G. Bettio, A. Ciofalo, Z. Diamant, J. Eckl-Dorna, WJ. Fokkens, C. Holzmeister, G. Mariën, S. Masieri, J. Otten, K. Scheckenbach, A. Tu, C. Bachert, CHRINOSOR consortium
520    9_
$a BACKGROUND: Pivotal studies with dupilumab demonstrated clinically relevant improvements in nasal polyp score, symptom score, and quality-of-life score in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). OBJECTIVE: We evaluated the effectiveness of dupilumab in a large-scale CRSwNP cohort from 6 European tertiary-care centers. METHODOLOGY: Nasal polyp score, Sinonasal Outcome Test 22 score, visual analog scale for total sinus symptoms, loss of smell, and nasal blockage, and Asthma Control Test (ACT) score were collected from hospital records and assessed at baseline and again at 24 and 52 weeks' treatment with dupilumab in CRSwNP patients. Treatment effectiveness was evaluated in relation to demographic and lifestyle factors, sinus surgery history, presence of comorbidities, and blood eosinophil counts (BEC). Treatment response was evaluated according to European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) 2021 criteria. RESULTS: All patient outcomes improved at 24 and 52 weeks' treatment compared to baseline. Dupilumab showed effectiveness independent of age, sex, body mass index, smoking status, prior sinus surgery, presence of asthma, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease, allergy, or baseline BEC. A total of 92.5% and 94.4% showed an improvement in at least 1 EUFOREA criterion at 24 and 52 weeks, respectively; 54.4% and 68.2% met all 4 of the more stringent EUFOREA criteria at 24 and 52 weeks, respectively. CONCLUSIONS: Real-world evaluation of dupilumab effectiveness demonstrates a robust and sustained response in at least two thirds of patients at 52 weeks' treatment. Favorable treatment response was independent of the number of sinus surgery procedures, major comorbidities, or baseline systemic levels of type 2 inflammation.
650    _2
$a lidé $7 D006801
650    12
$a nosní polypy $x farmakoterapie $x imunologie $7 D009298
650    12
$a sinusitida $x farmakoterapie $7 D012852
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a rýma $x farmakoterapie $7 D012220
650    _2
$a chronická nemoc $7 D002908
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a výsledek terapie $7 D016896
650    _2
$a kohortové studie $7 D015331
650    _2
$a senioři $7 D000368
650    _2
$a kvalita života $7 D011788
650    _2
$a rinosinusitida $7 D000096825
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Schneider, Sven $u Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
700    1_
$a de Kinderen, Joost $u Galenus Health, Hasselt, Belgium
700    1_
$a Reitsma, Sietze $u Department of Otorhinolaryngology and Head/Neck Surgery, Amsterdam University Medical Centres, Amsterdam, The Netherlands
700    1_
$a Cavaliere, Carlo $u Department of Sense Organs, Sapienza University, Rome, Italy
700    1_
$a Tomazic, Peter-Valentin $u Department of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria
700    1_
$a Morgenstern, Christina $u Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
700    1_
$a Mortuaire, Geoffrey $u Otorhinolaryngology-Head and Neck Department, Huriez Hospital, Centre Hospitalier Universitaire Lille, Lille, France
700    1_
$a Wagenmann, Martin $u Department of Otorhinolaryngology, Universitätsklinikum Düsseldorf, Dusseldorf, Germany
700    1_
$a Bettio, Giulia $u Galenus Health, Hasselt, Belgium
700    1_
$a Ciofalo, Andrea $u Department of Sense Organs, Sapienza University, Rome, Italy
700    1_
$a Diamant, Zuzana $u Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology & Transplantation, Katholieke Universiteit Leuven, Leuven, Belgium; Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; Department of Clinical Pharmacy and Pharmacology, University Groningen, University Medical Center Groningen, Groningen, The Netherlands
700    1_
$a Eckl-Dorna, Julia $u Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
700    1_
$a Fokkens, Wytske J $u Department of Otorhinolaryngology and Head/Neck Surgery, Amsterdam University Medical Centres, Amsterdam, The Netherlands
700    1_
$a Holzmeister, Clemens $u Department of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria
700    1_
$a Mariën, Gert $u Galenus Health, Hasselt, Belgium
700    1_
$a Masieri, Simonetta $u Department of Oral and Maxillofacial Sciences, Sapienza University, Rome, Italy
700    1_
$a Otten, Josje $u Department of Otorhinolaryngology and Head/Neck Surgery, Amsterdam University Medical Centres, Amsterdam, The Netherlands
700    1_
$a Scheckenbach, Kathrin $u Department of Otorhinolaryngology, Universitätsklinikum Düsseldorf, Dusseldorf, Germany
700    1_
$a Tu, Aldine $u Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
700    1_
$a Bachert, Claus $u Department of Otorhinolaryngology, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium; Clinic for ENT diseases and Head and Neck Surgery, University Clinic Münster, Münster, Germany
710    2_
$a CHRINOSOR consortium
773    0_
$w MED00002505 $t Journal of allergy and clinical immunology $x 1097-6825 $g Roč. 155, č. 2 (2025), s. 451-460
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39486595 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134642 $b ABA008
999    __
$a ok $b bmc $g 2311466 $s 1247190
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 155 $c 2 $d 451-460 $e 20241031 $i 1097-6825 $m Journal of allergy and clinical immunology $n J Allergy Clin Immunol $x MED00002505
LZP    __
$a Pubmed-20250415
Back

Find record

Citation metrics

Archiving options